Health & Fitness
Tue, February 14, 2012Mon, February 13, 2012Sun, February 12, 2012Fri, February 10, 2012Thu, February 9, 2012Wed, February 8, 2012Tue, February 7, 2012Mon, February 6, 2012Sun, February 5, 2012Sat, February 4, 2012Fri, February 3, 2012Thu, February 2, 2012Wed, February 1, 2012Keryx Biopharmaceuticals to Present at 14th Annual BIO CEO and Investor Conference
//health-fitness.news-articles.net/content/2012/ .. 14th-annual-bio-ceo-and-investor-conference.html
Published in Health and Fitness on Wednesday, February 8th 2012 at 5:40 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
Keryx Biopharmaceuticals to Present at 14th Annual BIO CEO and Investor Conference -- NEW YORK, Feb. 8, 2012 /PRNewswire/ --
Keryx Biopharmaceuticals to Present at 14th Annual BIO CEO and Investor Conference
Presentation Scheduled for Tuesday, February 14th at 9:00 a.m. ET
NEW YORK, Feb. 8, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: [ KERX ]) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 14th Annual BIO CEO and Investor Conference, which will be held at the Waldorf=Astoria Hotel in New York City. Mr. Bentsur's presentation is scheduled to take place on Tuesday, February 14, 2012 at 9:00 a.m. ET.
A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at [ http://investors.keryx.com ]. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: [ lfischer@keryx.com ]
SOURCE Keryx Biopharmaceuticals, Inc.
[ Back to top ]